实时全球研报
Risk Reward Update
研报英文原文证据摘录
Risk Reward Update
UpdateM
RiskRisk RewardReward– Joinn Laboratories- Joinn LaboratoriesChina Co Ltd (603127.SS)China Co Ltd (603127.SS)
Unrivaled leadership in China’s DSA market
PRICE TARGET Rmb43.50 EQUAL-WEIGHT THESIS
DCF - key assumptions: WACC of 10% and a terminal growth rate of 3.0%. RMB: HKD ▪Bellwether of China's DSA (drug safety
exchange rate of 1.1. assessment) industry.
entry barriers powered by global GLP Rmb30.91 ▪High
(good laboratory practice) qualifications,
Consensus Price Target Distribution Rmb12.60 Rmb45.83 strong track record and sufficient reserve of MS PT
lab monkeys.Source: Refinitiv, Morgan Stanley Research Mean Morgan Stanley Estimates
▪Fluctuating biotech funding both in China
and overseas causing volatility in contract
pricing and margins.
RISK REWARD CHART ▪Periodic re-valuation of lab monkey stock
compromises earnings quality.
CNY
Rmb65.00Rmb65.00(+28.41%)Rmb65.00(+28.41%)(+28.41%)
Consensus Rating Distribution
60 57% Overweight
Rmb50.62Rmb50.62Rmb50.62 29% Equal-weight
14% Underweight
45 Rmb43.50Rmb43.50(-14.07%)Rmb43.50(-14.07%)(-14.07%) MS Rating
Source: Refinitiv, Morgan Stanley Research
Rmb29.00Rmb29.00(-42.71%)Rmb29.00(-42.71%)(-42.71%) Risk Reward Themes
15 Secular Growth: Positive
Self-help: Positive
View descriptions of Risk Rewards Themes here
JUL '25 JAN '26 JUL '26 JUL '27
Key: Historical Stock Performance Current Stock Price Price Target
BULL CASE Rmb65.00 BASE CASE Rmb43.50 BEAR CASE Rmb29.00
72x bull-case 2027 EPS 52x base-case 2027 EPS 37x bear-case 2027 EPS
Projected earnings CAGR of 60%+, over Projected adjusted earnings CAGR of 46% Projected earnings CAGR of -10%, 2025-28e:
2025-28e: This presupposes blended over 2025-28e: This presupposes top-line This presupposes 1) revenue CAGRs much
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器